Clinical trials
Recurrent clinical trials
Below are recruiting recurrent clinical trials, each written for real people, not researchers. We’re tracking 1,424 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06685289RecruitingPhase 2
Donafenib and capecitabine after surgery for biliary cancer with high risk of return
This trial tests whether taking donafenib and capecitabine pills after surgery can help prevent biliary cancer from coming back in people who have a high risk of recurrence. It is for patients whose cancer was completely removed but had certain features that make recurrence more likely.
Nanjing, JiangsuAges 18–75 - NCT07518173RecruitingPhase 3
BL-M07D1 plus Pertuzumab for HER2-positive breast cancer
This trial tests whether a new cancer drug called BL-M07D1, combined with pertuzumab, works better or as well as standard chemotherapy for advanced HER2-positive breast cancer that has spread or come back. HER2-positive means the cancer cells have high levels of a protein called HER2, which makes them grow faster.
Guangzhou, GuangdongAges 18–75 - NCT05978050RecruitingPhase 3
Nimotuzumab plus paclitaxel for recurring stomach cancer
This Phase 3 trial tests whether adding nimotuzumab (an anti-EGFR antibody) to paclitaxel can improve outcomes for people with stomach or stomach-junction cancer that has returned and spread. It targets tumors with high EGFR (“EGFR high” on a pathology test) to see if this combination works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT05144152Recruiting
Testing M3 and FIT to predict polyp return in colon exams
This study checks how well two lab tests (M3 and FIT) can predict whether advanced colon polyps (adenomas) will come back. If you’ve had adenomas found on a prior colonoscopy, these results may help plan future surveillance.
Shatin, New TerritoriesAges 18 years+ - NCT06539481RecruitingPhase 4
ILUVIEN eye implant for kids with recurrent eye inflammation
This trial tests an eye implant (ILUVIEN) in children and teens ages 6 to 17 who have a type of eye inflammation called uveitis that keeps coming back. The implant releases medicine slowly over time to control inflammation and may help reduce the need for other treatments.
BerlinAges 6–17 - NCT07464366RecruitingPhase 2
MRG003 with or without putrelimab for salivary gland cancer
This trial tests a new drug combination (MRG003 with or without putrelimab) for people with advanced salivary gland cancer that has EGFR protein. It aims to see if the treatment is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06455046RecruitingPhase 2
New drug combo for advanced cervical cancer
This trial tests a new drug called AK104 combined with chemotherapy and a virus-based therapy for cervical cancer that has come back or spread. It might help people who have already tried standard treatments and need new options.
Fuzhou, FujianAges 18–75 - NCT06348719Recruiting
Robot vs. standard laparoscopy for early endometrial cancer
This trial compares two types of minimally invasive surgery (robot-assisted vs. conventional laparoscopy) for removing the uterus in people with early-stage, low- to intermediate-risk endometrial cancer. The goal is to see which approach offers the best value and outcomes.
LilleAges 18 years+ - NCT06157060Recruiting
Predicting liver cancer return after surgery with a blood test
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
Foshan, GuangdongAges 18–75 - NCT07064681Recruiting
AK104 plus TACE for resectable liver cancer
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06234098RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug called AT-1965 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07042295RecruitingPhase 2
Amivantamab or Cetuximab for Skin Cancer in People with Weakened Immune Systems
This trial tests two drugs, amivantamab with hyaluronidase or cetuximab, in people with weakened immune systems who have advanced skin cancer (squamous cell carcinoma). The goal is to see if these treatments can help shrink or control the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06822855Recruiting
Improving How We Predict Hodgkin Lymphoma Outcomes
This trial is looking at new ways to predict how Hodgkin lymphoma will respond to treatment. It collects blood and tumor samples at key times to see if these can help doctors make better treatment decisions in the future.
Milan, MIAges 18 years+ - NCT07039877RecruitingPhase 2
Low-dose venetoclax with itraconazole and TACL for relapsed or refractory ALL
This trial tests a combination of low-dose venetoclax (a targeted cancer pill) plus itraconazole (an antifungal) and chemotherapy drugs for adults with acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to first treatment.
Monterrey, Nuevo LeónAges 16–45 - NCT07139951Enrolling by invitationPhase 2
Heated Chemotherapy for Stomach Cancer at High Risk of Recurrence
This trial tests a special type of chemotherapy that is heated and delivered directly into the belly during surgery (called HIPEC). It uses two drugs, cisplatin and paclitaxel, and is for people with stomach cancer who are at high risk of the cancer returning in the lining of the belly.
Rochester, MinnesotaAges 18–80 - NCT07118202Recruiting
TheraBionic device for advanced liver cancer
This trial tests a device called TheraBionic P1 for people with advanced liver cancer that has not responded to other treatments. It may be an option if you have tried at least two prior therapies or cannot take standard treatments.
Bay City, MichiganAges 22 years+ - NCT07611266Recruiting
Predicting colorectal adenoma recurrence using combined medicine approach
This study helps predict which patients with colorectal adenomas (pre-cancerous growths) are at higher risk of them coming back or turning into cancer. Researchers will use both Western medical tests and Traditional Chinese Medicine patterns to create a prediction tool that may guide your follow-up care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07584954RecruitingPhase 1
Testing a new cancer immunotherapy in advanced solid tumors
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Fuzhou, FujianAges 18–75 - NCT07167342RecruitingPhase 4
Can a probiotic prevent polyp regrowth after colonoscopy?
This trial tests whether taking a probiotic called Clostridium Butyricum after colon polyp removal can lower the chance of polyps coming back. It is looking for people who had adenomas removed and are not already taking certain supplements or antibiotics.
Qingdao, ShandongAges 18–75 - NCT07475026RecruitingPhase 3
Combination therapy before surgery for high-risk liver cancer
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
TianjinAges 18–75 - NCT07371403Recruiting
Car-t cell therapy for relapsed or refractory acute lymphoblastic leukemia
This trial tests a type of immunotherapy called CAR-T cells that are made from your own blood cells and are designed to find and destroy leukemia cells. It is for patients whose leukemia has come back or hasn't gone away after other treatments.
AmmanAges 1 year+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT02523014RecruitingPhase 2
Drug combo for meningioma that keeps growing despite treatment
This Phase 2 trial tests several targeted medicines (given together or by specific assignment) for meningiomas inside the brain that are progressing or not fully removed after surgery. It may help slow the tumor’s growth and improve symptoms by blocking tumor growth pathways.
Birmingham, AlabamaAges 18 years+ - NCT07564141RecruitingPhase 3
New Drug for Recurrent Ovarian Cancer After Chemotherapy
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
Danbury, ConnecticutAges 18 years+
Hear when a new Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent?
- Yes. Clin2 currently lists 1,424 recruiting recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.